NCT00569023 is a NA clinical trial of alga Dunaliella bardawil in Night Blindness, sponsored by Sheba Medical Center.

Who is sponsoring NCT00569023?

NCT00569023 is sponsored by Sheba Medical Center.

What drugs are being tested in NCT00569023?

Interventions in NCT00569023: alga Dunaliella bardawil.

What condition does NCT00569023 study?

NCT00569023 studies Night Blindness.

Is NCT00569023 still recruiting?

NCT00569023 is currently completed. Last updated 26 June 2012.

Last reviewed 2012-06-26 · How we verify

NCT00569023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene

Completed NA Last updated 26 June 2012

What this trial tests

NA trial testing alga Dunaliella bardawil in Night Blindness in 7 participants. Completed in 1 July 2010.

Timeline

1 July 2007

Primary endpoint
1 August 2009

1 July 2010

Quick facts

Lead sponsor	Sheba Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	1 July 2007
Primary completion	1 August 2009
Estimated completion	1 July 2010
Sites	1 location across Israel

Drugs / interventions tested

alga Dunaliella bardawil — full drug profile →

Conditions studied

Night Blindness — all drugs for Night Blindness →

Sponsor

Sheba Medical Center

Who can join

Adults 18 to 75, any sex, with Night Blindness. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Electroretinogram responses
Time frame: Three months

Sponsor's own description

To assess the effect of oral administration of the alga Dunaliella bardawil containing approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers on visual functions patients with Congenital Stationary Night Blindness {Fundus albipunctatus).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Sheba Medical Center trials

Trials by the same sponsor.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00569023 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
Last refreshed: 26 June 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00569023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing